Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlitelimab - Kymab/Sanofi

Next Previous
Drug Profile

Amlitelimab - Kymab/Sanofi

Alternative Names: KY-1005; SAR-445229

Latest Information Update: 18 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymab
  • Developer Kymab; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Alopecia areata; Asthma; Autoimmune disorders; Coeliac disease; Hidradenitis suppurativa; Systemic scleroderma
  • No development reported Graft-versus-host disease

Most Recent Events

  • 13 Nov 2025 Sanofi completes a phase-III clinical trials in Atopic dermatitis (Monotherapy, Treatment-experienced) in Taiwan, South Korea, Poland, Israel, Israel, India, Germany, Greece, France, China, Chile, Brazil, Australia, Argentina (SC) (NCT06130566)
  • 01 Nov 2025 Sanofi completes a phase III SHORE trial in Atopic dermatitis (Treatment-experienced, Monotherapy) in Argentina, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Multinational, Spain, Turkey, USA (SC) (NCT06224348)
  • 10 Oct 2025 Sanofi terminates phase II trial in Hidradenitis suppurativa (Treatment-experienced) in Australia, Canada, Chile, France, Germany, Hungary, Italy, Poland, Portugal, Spain, USA (SC) (NCT06118099)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top